CoChat
Sign Up
Cited by 45Pregnancy and preeclampsia studiesNeurological Complications and SyndromesMaternal Mental Health During Pregnancy and Postpartum

Pravastatin in preeclampsia: A meta-analysis and systematic review

Open access
Mészáros, Balázs, Veres, Dániel Sándor, Nagyistók, Luca, Somogyi, Anikó, Rosta, Klára, Herold, Zoltán, Kukor, Zoltán, Valent, Sándor·2023·Frontiers in Medicine
DOI 10.3389/fmed.2022.1076372PMC PMC9880057
Open this paper in CoChat — free account

Abstract

Objective: To review of the efficacy and safety of pravastatin use for prophylaxis and treatment of preeclampsia. Design: Systematic review and meta-analysis of clinical studies evaluating pravastatin for treatment and/or prophylaxis of preeclampsia. Data collection: Two independent reviewers systematically searched data from PubMed, Scopus, Web of Science, Cochrane, Embase, and clinicaltrials.gov databases, for studies evaluating pravastatin for prevention of pre-eclampsia. Results: Fourteen studies were identified, including 1,570 pregnant women who received either pravastatin or placebo, published between 2003 and 2022. From these studies, 5 studies were identified for inclusion in the meta-analysis to evaluate the role of pravastatin use prior to 20 weeks of gestation, to prevent pre-eclampsia, Pravastatin treatment reduced the incidence of preeclampsia by 61% and premature birth by 45%. Among the newborns, there was a 45% reduction in intrauterine growth retardation (IUGR) in the treated group, as well as a 77% reduction in those receiving neonatal intensive care unit (NICU) admissions. Conclusion: Prophylactic treatment with pravastatin appears to reduce risk of developing pre-eclampsia as well as potentially lowering risk of IUGR, preterm birth, and NICU admission in neonates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmed.2022.1076372

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Statins did not increase teratogenic effects for individuals with familial hypercholesterolemia, and a meta-analysis of pravastatin in pregnant individuals showed a reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions.

    “Although the evidence is limited, statins did not increase teratogenic effects for individuals with familial hypercholesterolemia (147,148), and a meta-analysis of pravastatin in pregnant individuals showed a reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions (149).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [149]

  • A meta-analysis of pravastatin in pregnant individuals showed a reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions.

    “Although the evidence is limited, statins did not increase teratogenic effects for individuals with familial hypercholesterolemia (141,142), and a meta-analysis of pravastatin in pregnant individuals showed a reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions (143).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [143]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 64

  1. [2]Steegers E von Dadelszen P Duvekot J Pijnenborg R. Pre-eclampsia. Lancet. (2010) 376: 631– 44. 10.1016/S0140-6736(10)60279-6 20598363 · DOI · Paper page
  2. [3]Ananth C Keyes K Wapner R. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. (2013) 347: f6564. 10.1136/bmj.f6564 24201165 PMC3898425 · DOI · Paper page
  3. [4]Ishimwe J. Maternal microbiome in preeclampsia pathophysiology and implications on offspring health. Physiol Rep. (2021) 9: e14875. 10.14814/phy2.14875 34042284 PMC8157769 · DOI · Paper page
  4. [5]Ma’ayeh M Rood K Kniss D Costantine M. Novel interventions for the prevention of preeclampsia. Curr Hypertens Rep. (2020) 22: 17. 10.1007/s11906-020-1026-8 32052203 PMC8237364 · DOI
  5. [6]Gajzlerska-Majewska W Bomba-Opon D Wielgos M. Is pravastatin a milestone in the prevention and treatment of preeclampsia? J Perinat Med. (2018) 46: 825– 31. 10.1515/jpm-2017-0109 29570452 · DOI
  6. [7]Dymara-Konopka W Laskowska M Błażewicz A. Angiogenic imbalance as a contributor of preeclampsia. Curr Pharm Biotechnol. (2018) 19: 797– 815. 10.2174/1389201019666180925115559 30255753 · DOI
  7. [8]Xu T Zhou F Deng C Huang G Li J Wang X. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens. (2015) 17: 567– 73. 10.1111/jch.12541 25833349 PMC8031490 · DOI
  8. [9]Burton G Redman C Roberts J Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. (2019) 366: l2381. 10.1136/bmj.l2381 31307997 · DOI · Paper page
  9. [10]Koch C. Statin therapy. Curr Pharm Des. (2012) 18: 6284– 90. 10.2174/138161212803832335 22762471 · DOI
  10. [11]Mikhailidis D Athyros V. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol. (2014) 11: 72– 4. 10.1038/nrcardio.2013.209 24366071 · DOI
  11. [12]Smith D Costantine M. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol. (2022) 226: S1171– 81. 10.1016/j.ajog.2020.08.040 32818477 PMC8237152 · DOI
  12. [13]Pánczél Z Kukor Z Supák D Kovács B Kecskeméti A Czizel R Pravastatin induces NO synthesis by enhancing microsomal arginine uptake in healthy and preeclamptic placentas. BMC Pregnancy Childbirth. (2019) 19: 426. 10.1186/s12884-019-2507-0 31747921 PMC6868828 · DOI
  13. [14]Pánczél Z Supák D Kovács B Kukor Z Valent S. A pravasztatin hatása tetrahidrobiopterin-érzékeny és -rezisztens praeeclampsiás placenták NO-szintáz-aktivitására [Effect of pravastatin on tetrahydrobiopterin-sensitive and -resistant NO synthase activity of preeclamptic placentas]. Orv Hetil. (2020) 161: 389– 95. 10.1556/650.2020.31670 32115993 · DOI
  14. [15]Edison R Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. (2004) 350: 1579– 82. 10.1056/NEJM200404083501524 15071140 · DOI
  15. [16]Chang J Chen Y Chen I Lin W Chen Y Lin C. Perinatal outcomes after statin exposure during pregnancy. JAMA Netw Open. (2021) 4: e2141321. 10.1001/jamanetworkopen.2021.41321 34967881 PMC8719244 · DOI
  16. [17]Ison H Clarke S Knowles J. Familial hypercholesterolemia. In: Adam M Everman D Mirzaa G Pagon R Wallace S Bean L editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle (1993– 2022). 24404629
  17. [18]Vahedian-Azimi A Bianconi V Makvandi S Banach M Mohammadi S Pirro M A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis. (2021) 336: 1– 11. 34601188
  18. [19]de Alwis N Beard S Mangwiro Y Binder N Kaitu’u-Lino T Brownfoot F Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. Pregnancy Hypertens. (2020) 20: 83– 91. 10.1016/j.preghy.2020.03.004 32199147 · DOI
  19. [20]Taysi S Tascan A Ugur M Demir M. Radicals, oxidative/nitrosative stress and preeclampsia. Mini Rev Med Chem. (2019) 19: 178– 93. 30324879
  20. [21]Kukor Z Valent S. A nitrogén-monoxid-szintézis zavarai praeeclampsiában [Nitric oxide and preeclampsia]. Orv Hetil. (2010) 151: 2125– 35. 21147698
  21. [22]Alasztics B Kukor Z Pánczél Z Valent S. A praeeclampsia kórélettana a kétlépcsős modell tükrében [The pathophysiology of preeclampsia in view of the two-stage model]. Orv Hetil. (2012) 153: 1167– 76. 22835633
  22. [23]Salsoso R Guzmán-Gutiérrez E Sáez T Bugueño K Ramírez M Farías M Insulin restores L-arginine transport requiring adenosine receptors activation in umbilical vein endothelium from late-onset preeclampsia. Placenta. (2015) 36: 287– 96. 10.1016/j.placenta.2014.12.007 25573092 · DOI
  23. [24]Brownfoot F Tong S Hannan N Hastie R Cannon P Kaitu’u-Lino T. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth. (2016) 16: 117. 10.1186/s12884-016-0902-3 27207105 PMC4874016 · DOI
  24. [25]Chigusa Y Kawasaki K Kondoh E Mogami H Ujita M Fujita K Simvastatin inhibits oxidative stress via the activation of nuclear factor erythroid 2-related factor 2 signaling in trophoblast cells. J Obstet Gynaecol Res. (2016) 42: 36– 43. 10.1111/jog.12876 26556031 · DOI
  25. [26]Dong X Shi D. Simvastatin alleviates pathology in a rat model of preeclampsia involving ERK/MAPK pathway. Reprod Sci. (2017) 24: 1053– 61. 10.1177/1933719116678693 27856999 · DOI
  26. [27]Csomó K Belik A Hrabák A Kovács B Fábián O Valent S Effect of pravastatin and simvastatin on the reduction of cytochrome C. J Pers Med. (2022) 12: 1121. 10.3390/jpm12071121 35887618 PMC9321872 · DOI
  27. [28]Bauer A Banek C Needham K Gillham H Capoccia S Regal J Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension. (2013) 61: 1103– 10. 10.1161/HYPERTENSIONAHA.111.00226 23460290 PMC3909776 · DOI
  28. [29]Esteve-Valverde E Ferrer-Oliveras R Gil-Aliberas N Baraldès-Farré A Llurba E Alijotas-Reig J. Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet Gynecol Surv. (2018) 73: 40– 55. 10.1097/OGX.0000000000000522 29368790 · DOI
  29. [32]Sweeting M Sutton A Lambert P. What to add to nothing? use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. (2004) 23: 1351– 75. 10.1002/sim.1761 15116347 · DOI · Paper page
  30. [34]Paule R Mandel J. Consensus values and weighting factors. J Res Nat Bureau Stand. (1982) 87: 377– 87. PMC6768160 34566088
  31. [36]Higgins JPT Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21: 1539– 58. 10.1002/sim.1186 12111919 · DOI · Paper page
  32. [41]Costantine M Cleary K Hebert M Ahmed M Brown L Ren Z Eunice kennedy shriver national institute of child health and human development obstetric-fetal pharmacology research units network. safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. (2016) 214: 720.e1– e17. 10.1016/j.ajog.2015.12.038 26723196 PMC4884459 · DOI
  33. [42]Costantine M West H Wisner K Caritis S Clark S Venkataramanan R Eunice kennedy shriver national institute of child health and human development obstetric-fetal pharmacology research centers (OPRC) network, Bethesda, MD. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. (2021) 225: 666.e1– e15. 10.1016/j.ajog.2021.05.018 34033812 PMC8611118 · DOI
  34. [43]Akbar M Yosediputra A Pratama R Fadhilah N Sulistyowati S Amani F INOVASIA study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1/PlGF levels. Am J Perinatol. (2021). [Epub ahead of print]. 10.1055/a-1673-5603 34666379 · DOI
  35. [44]Akbar M Azis M Riu D Wawengkang E Ernawati E Bachnas M INOVASIA study: a multicenter randomized clinical trial of pravastatin to prevent preeclampsia in high-risk patients. Am J Perinatol. (2022). [Epub ahead of print]. 10.1055/a-1798-1925 35292944 · DOI
  36. [45]Kupferminc M Kliger C Rimon E Asher-Landsberg J Skornick-Rapaport A Gamzu R Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study. J Matern Fetal Neonatal Med. (2022) 35: 8055– 61. 10.1080/14767058.2021.1940940 34154497 · DOI
  37. [46]Tomimatsu T Mimura K Matsuzaki S Endo M Kumasawa K Kimura T. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. Int J Mol Sci. (2019) 20: 4246. 10.3390/ijms20174246 31480243 PMC6747625 · DOI
  38. [47]Lefkou E Mamopoulos A Dagklis T Vosnakis C Rousso D Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. (2016) 126: 2933– 40. 10.1172/JCI86957 27454295 PMC4966313 · DOI
  39. [48]Mendoza M Ferrer-Oliveras R Bonacina E Garcia-Manau P Rodo C Carreras E Evaluating the effect of pravastatin in early-onset fetal growth restriction: a nonrandomized and historically controlled pilot study. Am J Perinatol. (2021) 38: 1472– 9. 10.1055/s-0040-1713651 32615618 · DOI
  40. [49]Döbert M Varouxaki A Mu A Syngelaki A Ciobanu A Akolekar R Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation. (2021) 144: 670– 9. 10.1161/CIRCULATIONAHA.121.053963 34162218 · DOI
  41. [50]Ahmed A Williams D Cheed V Middleton L Ahmad S Wang K StAmP trial Collaborative Group, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. (2020) 127: 478– 88. 10.1111/1471-0528.16013 31715077 PMC7063986 · DOI
  42. [51]Lefkou E Varoudi K Pombo J Jurisic A Jurisic Z Contento G Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. Biochem Pharmacol. (2020) 182: 114217. 10.1016/j.bcp.2020.114217 32926874 · DOI
  43. [52]Jurisic A Jurisic Z Lefkou E Girardi G. Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction. Vascul Pharmacol. (2021) 137: 106824. 10.1016/j.vph.2020.106824 33249273 · DOI
  44. [53]Lefkou E Mamopoulos A Fragakis N Dagklis T Vosnakis C Nounopoulos E Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension. (2014) 63: e118– 9. 10.1161/HYPERTENSIONAHA.114.03115 24591337 · DOI
  45. [54]Brownfoot F Tong S Hannan N Binder N Walker S Cannon P Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. (2015) 66: 687– 97. 10.1161/HYPERTENSIONAHA.115.05445 26222708 · DOI
  46. [55]Saito J Kaneko K Abe S Yakuwa N Kawasaki H Suzuki T Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and lactation: a case study. J Clin Pharm Ther. (2022) 47: 703– 6. 10.1111/jcpt.13590 34951046 · DOI
  47. [56]Loussert L Vidal F Parant O Hamdi S Vayssiere C Guerby P. Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat Diagn. (2020) 40: 519– 27. 10.1002/pd.5645 31955436 · DOI
  48. [57]Martinelli I Ruggenenti P Cetin I Pardi G Perna A Vergani P Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. (2012) 119: 3269– 75. 10.1182/blood-2011-11-391383 22289887 PMC3321853 · DOI
  49. [58]Atallah A Lecarpentier E Goffinet F Doret-Dion M Gaucherand P Tsatsaris V. Aspirin for prevention of preeclampsia. Drugs. (2017) 77: 1819– 31. 10.1007/s40265-017-0823-0 29039130 PMC5681618 · DOI
  50. [60]Wright D Nicolaides K. Aspirin delays the development of preeclampsia. Am J Obstet Gynecol. (2019) 220: 580.e1– e6. 10.1016/j.ajog.2019.02.034 30797761 · DOI
  51. [61]Sureda A Pons A. Arginine and citrulline supplementation in sports and exercise: ergogenic nutrients? Med Sport Sci. (2012) 59: 18– 28. 10.1159/000341937 23075551 · DOI
  52. [62]Mastrolia S Novack L Thachil J Rabinovich A Pikovsky O Klaitman V LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis. Thromb Haemost. (2016) 116: 868– 78. 10.1160/TH16-02-0169 27440387 · DOI
  53. [63]Bartsch E Medcalf K Park A Ray J. High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. (2016) 353: i1753. 10.1136/bmj.i1753 27094586 PMC4837230 · DOI · Paper page
  54. [64]Robillard P Dekker G Scioscia M Bonsante F Iacobelli S Boukerrou M Increased BMI has a linear association with late-onset preeclampsia: a population-based study. PLoS One. (2019) 14: e0223888. 10.1371/journal.pone.0223888 31622409 PMC6797165 · DOI
  55. [65]Poon L Shennan A Hyett J Kapur A Hadar E Divakar H The international federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. (2019) 145 (Suppl. 1): 1– 33. 10.1002/ijgo.12802 31111484 PMC6944283 · DOI
  56. [66]Capriglione S Gulino F Latella S De Felice G Filippini M Farinelli M Results of a five-year experience in first trimester preeclampsia screening. J Clin Med. (2022) 11: 4555. 10.3390/jcm11154555 35956169 PMC9369645 · DOI
  57. [67]Huang T Bedford H Rashid S Rasasakaram E Priston M Mak-Tam E Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia. BMC Pregnancy Childbirth. (2022) 22: 190. 10.1186/s12884-022-04514-4 35260099 PMC8903171 · DOI
  58. [68]Mazer Zumaeta A Wright A Syngelaki A Maritsa V Da Silva A Nicolaides K. Screening for pre-eclampsia at 11-13 weeks’ gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. (2020) 56: 400– 7. 10.1002/uog.22093 32441401 · DOI
  59. [69]Capriglione S Plotti F Terranova C Gulino F Di Guardo F Lopez S Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. J Matern Fetal Neonatal Med. (2020) 33: 677– 86. 10.1080/14767058.2018.1495191 29954233 · DOI
  60. [70]Lecarpentier É Vieillefosse S Haddad B Fournier T Leguy M Guibourdenche J Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia. Ann Biol Clin. (2016) 74: 259– 67. 10.1684/abc.2016.1158 27237799 · DOI
  61. [71]Petersen E Mitchell A Carey J Werler M Louik C Rasmussen S. National birth defects prevention study. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A. (2008) 146A: 2701– 5. 10.1002/ajmg.a.32493 18792975 · DOI
  62. [72]Miller C Kodavanti U Stewart E Schaldweiler M Richards J Ledbetter A Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats. Reprod Toxicol. (2019) 83: 63– 72. 10.1016/j.reprotox.2018.12.002 30528429 PMC6582633 · DOI
  63. [73]Zhang M Wan P Ng K Singh K Cheng T Velickovic I Preeclampsia among african american pregnant women: an update on prevalence, complications, etiology, and biomarkers. Obstet Gynecol Surv. (2020) 75: 111– 20. 10.1097/OGX.0000000000000747 32105335 · DOI
  64. [74]Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. (2009) 33: 130– 7. 10.1053/j.semperi.2009.02.010 19464502 · DOI · Paper page

Cited by

Sorted by citations

Authors
Mészáros, B., Veres, D. S., Nagyistók, L., Somogyi, A., Rosta, K., Herold, Z., Kukor, Z., & Valent, S.
Affiliations
  • Semmelweis University (HU)
  • Medical University of Vienna (AT)
Corresponding author
Kukor, Zoltán
ORCID
Venue
Frontiers in Medicine
Publisher
Frontiers Media SA
Published
2023-01-13
Volume
9
Pages
1076372-1076372
ISSN
2296-858X (ISSN-L)
DOI
10.3389/fmed.2022.1076372
PMC
PMC9880057
OpenAlex
W4315782544
Cited by
45
References
9
Citations by year
2026: 10 · 2025: 21 · 2024: 12 · 2023: 2
FWCI
2.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Semmelweis Egyetem (EFOP-3.6.3- VEKOP-16-2017-00009)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Neurological Complications and Syndromes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
pravastatin, preeclampsia, preeclampsia prevention, fetal growth restriction, preterm birth, neonatal intensive care admission, drug safety in pregnancy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review